S21 Transcriptional Super Enhancers and Cancer

Program: Symposia
Basic/Translational Session
Friday, April 1, 2016: 4:45 PM-6:15 PM
Room 205 (BCEC)
Chair:
Donald Benedict DeFranco, PhD, University of Pittsburgh School of Medicine, Pittsburgh, PA

Nothing to Disclose: DBD
4:45 PM
Richard A Young, PhD, Department of Biology, Whitehead Institute, Massachusetts Institute of Technology, Cambridge, MA
Disclosures:
RAY: Board Member, Syros Pharmaceuticals.
5:15 PM
Christopher Kevin Glass, MD, PhD, Department of Cellular & Molecular Medicine, University of California-San Diego, La Jolla, CA
Nothing to Disclose: CKG
5:45 PM
Mathieu Lupien, PhD, University of Toronto, Toronto, ON, Canada
Nothing to Disclose: ML
See more of: Symposia

 

The Endocrine Society would like to thank the following organizations for their support: AbbVie Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiasma, Inc.; Corcept Therapeutics Incorporated; Eisai, Inc.; Ethicon Endo-Surgery, Inc.; Genzyme, a Sanofi company, Ipsen Biopharmaceuticals, Inc.; Leona M. and Harry B. Helmsley Charitable Trust; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Pfizer, Inc.; Shire